CAMBRIDGE, Mass.–(BUSINESS WIRE)–Syros Pharmaceuticals (NASDAQ:SYRS), a leader in the development of
medicines that control the expression of genes, today announced that its
Chief Executive Officer, Nancy Simonian, M.D., will participate in a
fireside chat at the JMP Securities Life Sciences Conference. Details
are as follows:
JMP Securities Life Sciences Conference:
Time: 1:00 p.m. ET
Location: The St. Regis New York, 2
East 55th Street, New York, NY
A live webcast of the fireside chat will be available on the Investors &
Media section of the Syros website at www.syros.com.
An archived replay will be available for approximately 30 days following
the fireside chat.
About Syros Pharmaceuticals
Syros is pioneering the
understanding of the non-coding regulatory region of the genome to
advance a new wave of medicines that control the expression of genes.
Syros has built a proprietary platform that is designed to
systematically and efficiently analyze this unexploited region of DNA to
identify and drug novel targets linked to genomically defined patient
populations. Because gene expression is fundamental to the function of
all cells, Syros’ gene control platform has broad potential to create
medicines that achieve profound and durable benefit across a range of
diseases. Syros is currently focused on cancer and monogenic diseases
and is advancing a growing pipeline of gene control medicines. Syros’
lead drug candidates are SY-1425, a selective RARα agonist in a Phase 2
clinical trial for genomically defined subsets of patients with acute
myeloid leukemia and myelodysplastic syndrome, and SY-1365, a selective
CDK7 inhibitor in a Phase 1 clinical trial for patients with ovarian and
breast cancers. Syros is also developing a deep preclinical and
discovery pipeline, including SY-5609, an oral CDK7 inhibitor, as well
as programs in immuno-oncology and sickle cell disease. Led by a team
with deep experience in drug discovery, development and
commercialization, Syros is located in Cambridge, Mass.
Stern Investor Relations, Inc.